Citigroup Maintains Buy on Quest Diagnostics, Raises Price Target to $185
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Patrick Donnelly maintains a Buy rating on Quest Diagnostics and raises the price target from $165 to $185.
October 23, 2024 | 1:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup analyst Patrick Donnelly has reaffirmed a Buy rating for Quest Diagnostics and increased the price target from $165 to $185, indicating a positive outlook for the stock.
The reaffirmation of a Buy rating and an increase in the price target by a major financial institution like Citigroup suggests confidence in Quest Diagnostics' future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100